Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Celecoxib

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_988-2

Synonyms

Characteristics

Celecoxib, a diaryl-substituted pyrazole drug, was developed by G. D. Searle & Company and is currently marketed by Pfizer Incorporated under the brand names Celebrex and Celebra. Celecoxib is a member of the class of agents known as non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are the most commonly used therapeutic agents for the treatment of acute pain, fever, menstrual symptoms, osteoarthritis, and rheumatoid arthritis. Because of their ability to reduce tissue inflammation, which is often associated with tumorigenesis at various sites in the body (e.g., gastrointestinal tract and lung), celecoxib and certain other NSAIDs are also considered to have a potential in cancer chemoprevention as exemplified by their ability to prevent the formation and decrease the size of polyps in familial adenomatous polyposis (FAP) patients. Orally administered celecoxib...

Keywords

Familial Adenomatous Polyposis PI3K Pathway Human Prostate Cancer Cell Mitochondrial Membrane Permeabilization Cancer Chemoprevention 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

References

  1. Chun KS, Surh JY (2006) Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 68:1089–1100CrossRefGoogle Scholar
  2. Grosch S, Maier TJ, Schiffmann S et al (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98:736–747CrossRefPubMedGoogle Scholar
  3. Kismet K, Akay MT, Abbasoglu O et al (2004) Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev 28:127–142CrossRefPubMedGoogle Scholar
  4. Psaty BM, Potter JD (2006) Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med 355:950–952CrossRefPubMedGoogle Scholar
  5. Schroeder CP, Kadara H, Lotan D et al (2006) Involvement of mitochondrial and akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. Cancer Res 66:9762–9770CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Pharmaceutical SciencesThe University of Colorado at Denver and Health Sciences CenterDenverUSA
  2. 2.Department of Thoracic Head and Neck Medical OncologyThe University of Texas, MD Anderson Cancer CenterHoustonUSA